Evidence map›Paper›PMID 33127888›Full record

ArticleNPJ biofilms and microbiomes2020

Engineered lactobacilli display anti-biofilm and growth suppressing activities against Pseudomonas aeruginosa.

Todd C Chappell, Nikhil U Nair

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ biofilms and microbiomes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Todd C ChappellDepartment of Chemical & Biological Engineering, Tufts University, Medford, MA, USA.
Nikhil U NairDepartment of Chemical & Biological Engineering, Tufts University, Medford, MA, USA. nikhil.nair@tufts.edu.ORCID 0000-0001-7737-1385
Tufts University · US

Funding

Metabolic engineering in humans: Altered gut microbes as a therapeutic platformDP2HD091798 · NICHD · TUFTS UNIVERSITY MEDFORD · PI NAIR, NIKHIL UNNI · 2016 to 2016
$2.3M
NICHD NIH HHS DP2 HD091798
6 · The paper itself

Abstract

Biofilms are an emerging target for new therapeutics in the effort to address the continued increase in resistance and tolerance to traditional antimicrobials. In particular, the distinct nature of the biofilm growth state often means that traditional antimcirobials, developed to combat planktonic cells, are ineffective. Biofilm treatments are designed to both reduce pathogen load at an infection site and decrease the development of resistance by rendering the embedded organisms more susceptible to treatment at lower antimicrobial concentrations. In this work, we developed a new antimicrobial treatment modality using engineered lactic acid bacteria (LAB). We first characterized the natural capacity of two lactobacilli, L. plantarum and L. rhamnosus, to inhibit P. aeruginosa growth, biofilm formation, and biofilm viability, which we found to be dependent upon the low pH generated during culture of the LAB. We further engineered these LAB to secrete enzymes known to degrade P. aeruginosa biofilms and show that our best performing engineered LAB, secreting a pathogen-derived enzyme (PelA

Indexed as

Anti-Bacterial AgentsBiofilmsLacticaseibacillus rhamnosusLactiplantibacillus plantarumLactobacillusMetabolic EngineeringMicrobial Sensitivity TestsMicrobial ViabilityPseudomonas aeruginosaAnti-Bacterial Agents

Identifiers

PMID33127888
PMCPMC7599214
OpenAlexW3096682950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.